Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is
the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the …

Hepatocellular carcinoma (HCC) is the second leading cause of death due to cancer.
Although there are different treatment options, these strategies are not efficient in terms of …

Hepatocellular carcinoma (HCC) is one of the common and fatal malignancies, which is a
significant global health problem. The clinical applicability of traditional surgery and other …

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, and it
usually occurs following chronic liver disease. Although some progress has been made in …

Hepatocellular carcinoma (HCC) has emerged the culprit of cancer-related mortality
worldwide with its dismal prognosis climbing. In recent years, ground-breaking progress has …

With the high morbidity and mortality, hepatocellular carcinoma (HCC) represents a major
yet growing burden for our global community. The relapse-prone nature and drug resistance …

Epigenetic dysregulation of cell cycle is a hallmark of tumorigenesis in multiple cancers,
including hepatocellular carcinoma (HCC). Nonetheless, the epigenetic mechanisms …

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved
for the treatment of subsets of patients with hormone receptor positive (HR+) breast cancer …

Introduction: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and
the third cancer-related cause of death worldwide. In recent years, several systemic therapy …